Tumour immune characterisation of primary triple-negative breast cancer using automated image quantification of immunohistochemistry-stained immune cells

被引:0
|
作者
Roostee, Suze [1 ,2 ,4 ]
Ehinger, Daniel [1 ,3 ,4 ]
Jonsson, Mats [1 ,4 ]
Phung, Bengt [1 ,4 ]
Jonsson, Goeran [1 ,4 ]
Sjodahl, Gottfrid [3 ,4 ]
Staaf, Johan [1 ,2 ,4 ]
Aine, Mattias [1 ,4 ]
机构
[1] Lund Univ, Dept Clin Sci Lund, Div Oncol, S-22381 Lund, Sweden
[2] Lund Univ, Div Translat Canc Res, Dept Lab Med, S-22381 Lund, Sweden
[3] Skane Univ Hosp, Dept Genet Pathol & Mol Diagnost, Lund, Sweden
[4] Lund Univ, Dept Translat Med, Malmo, Sweden
来源
SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期
关键词
INFILTRATING LYMPHOCYTES; PROGNOSTIC VALUE; P53; PREDICTOR; PHENOTYPE; TRIALS;
D O I
10.1038/s41598-024-72306-1
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The tumour immune microenvironment (TIME) in breast cancer is acknowledged with an increasing role in treatment response and prognosis. With a growing number of immune markers analysed, digital image analysis may facilitate broader TIME understanding, even in single-plex IHC data. To facilitate analyses of the latter an open-source image analysis pipeline, Tissue microarray MArker Quantification (TMArQ), was developed and applied to single-plex stainings for p53, CD3, CD4, CD8, CD20, CD68, FOXP3, and PD-L1 (SP142 antibody) in a 218-patient triple negative breast cancer (TNBC) cohort with complementary pathology scorings, clinicopathological, whole genome sequencing, and RNA-sequencing data. TMArQ's cell counts for analysed immune markers were on par with results from alternative methods and consistent with both estimates from human pathology review, different quantifications and classifications derived from RNA-sequencing as well as known prognostic patterns of immune response in TNBC. The digital cell counts demonstrated how immune markers are coexpressed in the TIME when considering TNBC molecular subtypes and DNA repair deficiency, and how combination of immune status with DNA repair deficiency status can improve the prognostic stratification in chemotherapy treated patients. These results underscore the value and potential of integrating TIME and specific tumour intrinsic alterations/phenotypes for the molecular understanding of TNBC.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] The role of metabolic reprogramming in immune escape of triple-negative breast cancer
    Bao, Ruochen
    Qu, Hongtao
    Li, Baifeng
    Cheng, Kai
    Miao, Yandong
    Wang, Jiangtao
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [32] Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer
    Gregorio, Ana C.
    Lacerda, Manuela
    Figueiredo, Paulo
    Simoes, Sergio
    Dias, Sergio
    Moreira, Joao Nuno
    PATHOLOGY & ONCOLOGY RESEARCH, 2018, 24 (04) : 701 - 716
  • [33] Erythropoietin induces tumour progression and CD39 expression on immune cells in a preclinical model of triple-negative breast cancer
    Bessoles, Stephanie
    Chiron, Andrada
    Sarrabayrouse, Guillaume
    De La Grange, Pierre
    Abina, Amine M.
    Hacein-Bey-Abina, Salima
    IMMUNOLOGY, 2024, 173 (02) : 360 - 380
  • [34] VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer
    Cao, Xi
    Ren, Xinyu
    Zhou, Yidong
    Mao, Feng
    Lin, Yan
    Wu, Huanwen
    Sun, Qiang
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [35] Spatial Distribution of Immune Cells Drives Resistance to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
    Donati, Benedetta
    Reggiani, Francesca
    Torricelli, Federica
    Santandrea, Giacomo
    Rossi, Teresa
    Bisagni, Alessandra
    Gasparini, Elisa
    Neri, Antonino
    Cortesi, Laura
    Ferrari, Guglielmo
    Bisagni, Giancarlo
    Ragazzi, Moira
    Ciarrocchi, Alessia
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (01) : 120 - 134
  • [36] Single cell transcriptomics of the immune cells during chemotherapy in triple-negative breast cancer patients
    Frolova, A.
    Gerashchenko, T. S.
    Patysheva, M.
    Fedorov, A. A.
    Bragina, O.
    Garbukov, E.
    Cherdyntseva, N.
    Korobeynikov, V. Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S194 - S194
  • [37] SIGNIFICANTLY DIFFERENT IMMUNE MICROENVIRONMENT BETWEEN TRIPLE-NEGATIVE BREAST CANCER WITH AND WITHOUT NEOADJUVANT CHEMOTHERAPY THROUGH MULTIPLEX IMMUNOHISTOCHEMISTRY
    Lee, Miseon
    Lee, Hyun
    Gong, Gyungyub
    Lee, Hee Jin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1004 - A1004
  • [38] Preliminary characterisation of the spatial immune and vascular environment in triple negative basal breast carcinomas using multiplex fluorescent immunohistochemistry
    Takano, Elena A.
    Jana, Metta K.
    Gonzalez, Luis E. Lara
    Pang, Jia-Min B.
    Salgado, Roberto
    Loi, Sherene
    Fox, Stephen B.
    PLOS ONE, 2025, 20 (01):
  • [39] Developing an immune signature for triple-negative breast cancer to predict prognosis and immune checkpoint inhibitor response
    Wang, Ce
    Feng, Guoshuang
    Zhu, Jingjing
    Wei, Kecheng
    Huang, Chen
    Wu, Zhenyu
    Yu, Yongfu
    Qin, Guoyou
    FUTURE ONCOLOGY, 2022, 18 (09) : 1055 - 1066
  • [40] Identification of hypoxia-immune-related signatures for predicting immune efficacy in triple-negative breast cancer
    Wang, Luping
    Han, Haote
    Ma, Jiahui
    Feng, Yue
    Han, Zhuo
    Maharaj, Vinesh
    Tian, Jingkui
    Zhu, Wei
    Li, Shouxin
    Shao, Xiying
    ONCOLOGIE, 2024, 26 (03) : 433 - 444